tbuckley/cabot-search huggingface dataset:
Accuracy of magnetic resonance imaging in predicting residual disease in patients treated for stage IB2/II cervical carcinoma with chemoradiation therapy: Correlation of radiological findings with histology of the cervix
Authors: P. Morice, E. Vincens, C. Balleyguier, A. Rey, C. Uzan, E. Zareski, Y. Zafrani, P. Pautier, C. Lhommé, D. Castaigne, C. Haie-Meder
Journal: Journal of Clinical Oncology (2008)

16524 Background: The evaluation of residual disease (RD) after chemoradiation therapy (CRT) in stage IB2/II cervical carcinoma is conventionally based on clinical and radiological examinations (particularly Magnetic Resonance Imaging/MRI) performed 4 to 8 weeks after the end of treatment. Very few specific papers have correlated MRI and histological findings in cervix cancer. This is the aim of the present study. Methods: A retrospective review was undertaken of patients fulfilling the following inclusion criteria: 1. stage IB2/II cervical cancer 2. external radiotherapy (45 Gy) with concomitant chemotherapy (cisplatin 40 mg/m2/week) followed by utero-vaginal brachytherapy (15Gy to the intermediate risk CTV); 3. MRI performed 4 to 8 weeks after brachytherapy and 4. completion surgery including at least a hysterectomy. Post-surgical histological findings and MRI results were compared. Results: Forty-four patients (17 stage IB2 and 27 stage II) treated between 2003 and 2006 fulfilled all the inclusion criteria. Twelve patients (27%) had achieved a radiological complete response, 16 (36.5%) had unclassified lesions (RD or “fibrosis”) and 16 (36.5%) had radiological residual tumor. In terms of histological results, 19 patients (43%) had no residual disease, 10 (23%) had minimal residual disease (isolated cells or measuring a few millimeters), 2 (5%) had residual disease < 1 cm and 13 (29%) had residual disease > 1 cm. The sensitivity and the specificity of MRI in evaluating residual disease > 1 cm were respectively 87% and 52%. Conclusions: Residual disease evaluation 4 to 8 weeks after CRT with MRI is difficult and the risk of false positive result is higher than in case of MRI staging before treatment in patients with stage IB2/II cervical cancer. Other procedures or MRI improvement, such as MRI diffusion, should be evaluated for more accurate detection of residual disease in patients at the end of CRT. No significant financial relationships to disclose.
A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
Authors: N. M. Reddy, R. Simmons, M. Caldwell, M. H. Jagasia, D. S. Morgan, S. I. Park, J. P. Greer, K. L. Richards
Journal: Journal of Clinical Oncology (2011)

TPS138 Background: Approximately 40% patients with an intermediate/high to high-risk IPI score will relapse in the first year after completion of standard therapy with R-CHOP. Lenalidomide, an immunomodulatory drug, has activity in relapsed diffuse large B-cell lymphoma (DLBCL). Our pre-clinical data demonstrated that lenalidomide enhances the natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity of rituximab in lymphoma cell lines, inhibits angiogenesis, and alters cytokine production. Methods: This is a phase II randomized study of lenalidomide versus lenalidomide and rituximab. The primary endpoint of the study is to assess the one-year relapse-free survival for patients treated with lenalidomide alone (Arm A) or the combination of lenalidomide and rituximab (Arm B). We expect that a 25% difference in relapse rates compared with current standard therapy will have clinical significance. With a sample size of 32 in each arm, we will have 80% power to detect a difference of 25% between the null hypothesis that the one-year relapse rate is 40% and the alternative hypothesis that the one-year relapse rate is 15% using a two-sided significance level of 2.5%. DLBCL patients with int/high or high-risk IPI score or patients with a positive PET scan mid-therapy will be eligible for the study. Patients on arm A will receive lenalidomide at a dose of 25 mg daily for 21 days of 28 days. Patients on arm B will receive lenalidomide at a dose of 20 mg daily for 21 days along with rituximab on day 8 of even-numbered cycles. Treatment on both arms will be continued for one year. Treatment will be discontinued for disease progression. Lenalidomide dose adjustments are incorporated in the protocol. Correlative studies include performing cytokine analysis at various time intervals (sIL-2R, IL-6, IL-15, IL-12, TNF-a, and IFN-g). Flow cytometric analysis will be performed to assess the change in the number of peripheral blood NK cells (CD4, CD8 and CD56). Genotyping analysis of potentially prognostic DNA polymorphisms (in FCGR3A) will be performed.Thus far, 20 patients of the planned 64 patients have been enrolled.
Sun-protective behaviors, vitamin D, and skin cancer: A systematic review.
Authors: S. Jang, S. S. Venna
Journal: Journal of Clinical Oncology (2011)

e19712 Background: Sun-protective behavior (SPB) is promoted for the primary and secondary prevention of skin cancer. Vitamin D (Vit D) can be obtained from oral intake or via cutaneous synthesis. We hypothesize that SPB is associated with an increased risk of Vit D deficiency. Methods: We conducted a systematic review of the published literature on SPB and Vit D in skin cancer survivors or high risk patients for skin cancer. We searched original articles from PubMed and examined reference lists thru December, 2010. Results: Six articles were included. Two studies in xeroderma pigmentosum (XP) patients concluded the lack of association between SPB and Vit D level. Studies in renal transplant and basal cell nevus syndrome (BCNS) showed a high risk of Vit D deficiency in patients with SPB compared to the general population. There was one study among a cohort of skin cancer survivors which did not show a difference in the prevalence of Vit D deficiency between the survivors with and without SPB. Only two studies (DeLong, Kraemer) assessed Vit D intake. Conclusions: Results of published studies on SPB and Vit D remain inconclusive. Prospective cohort studies with adequate sample size and adjustment for Vit D intake is warranted to evaluate this potential association. Author Year Population Type Results Conclusion DeLong 2010 Skin cancer survivor; sun protected (n=76) vs. not (n=78) Cross-sectional 25(OH)D ≤ 20ng/mL 18% vs. 16% No relationship between Vit D level and SPB Tang 2010 BCNS (n=41) vs. general population (n=360) Retrospective cohort 25(OH)D ≤ 20ng/mL 56% vs. 18% BCNS patients may be at increased risk of Vit D deficiency Hoesl 2010 XP (n= 15) Cross-sectional 25(OH)D ≤ 25ng/mL 67% No association between duration of SPB and Vit D level Ulrich 2009 Organ transplant recipients; sun screen (n=60) vs. control (n=60) Prospective, case control Mean 25(OH)D 53ng/mL vs. 60ng/mL Not reported Querings 2006 Renal transplant recipients with sun protection (n=31) vs. general population (n=31) Case control Mean 25(OH)D 10.9ng/mL vs. 20ng/mL High risk of Vit D deficiency in renal transplant recipients Kraemer 1997 XP (n=9) Cohort Mean 25(OH)D 17.8ng/mL Despite SPB normal Vit D can be maintained 25(OH)D: 25-hydroxyvitamin D
Transient Osteoporosis of the Hip on FDG PET/CT
Authors: Gary A. Ulaner, Peter Sawan
Journal: Clinical Nuclear Medicine (2017)

Transient osteoporosis of the hip (TOH) is characterized by bone pain, osteopenia, and bone marrow edema in the absence of trauma. We present a 59-year-old man with chronic lymphocytic leukemia who underwent 18F-FDG PET/CT. 18F-FDG PET/CT demonstrated mildly FDG-avid lymph nodes consistent for chronic lymphocytic leukemia, as well as FDG-avidity in the right femoral head with corresponding osteopenia, rather than a focal lytic lesion. MR demonstrated bone marrow edema consistent with TOH. TOH is benign and self-limiting. Corresponding imaging may prevent misdiagnosis of benign FDG-avid TOH as other more severe hip processes such as tumors or infection.
Novel chemotherapy combinations for metastatic gastric adenocarcinoma (mAGC): An updated meta-analysis.
Authors: Anna Dorothea Wagner, Markus Moehler, Wilfried Grothe, Johannes Haerting, Susanne Unverzagt
Journal: Journal of Clinical Oncology (2015)

125 Background: Despite the successful integration of targeted therapies, chemotherapy remains the mainstay of treatment for mAGC. Uncertainty remains regarding the choice of the regimen. Methods: We searched: Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE until February 2014; proceedings from ECCO, ESMO, ASCO until June 2014 with Selection criteria: Randomised controlled trials on chemotherapy in mAGC. Objectives: To assess and compare the effects on overall survival of regimens containing: 1) irinotecan (I) vs non-I, 2) docetaxel (D) vs non-D, 3) capecitabine (C) vs 5-FU, 4) S-1 vs 5-FU, 5) oxaliplatin (O) vs the same regimen containing cisplatin. For 1) and 2), substitutive (other chemotherapy substituted by I or D) and additive comparisons (I or D added) were analyzed separately. Results: The meta-analyses of overall survival included: Comparison 1) a. Substitutive: 5 trials, 724 patients (pts), with a HR of 0.85 (95% CI 0.73-0.99), b. Additive: 3 trials, 500 pts, with a HR of 0.88 (95% CI 0.76-1.03), both in favor of the I-containing regimens. Comparison 2) In total, 6 trials, 1702 pts, with a HR of 0.89 (95% CI 0.80-0.99) in favor of patients treated with D. a. Substitutive: 3 trials, 479 pts, with a HR of 1.05 (95% CI 0.87-1.27) in favor of patients treated without D. b. Additive: 3 trials, 1223 pts, with a HR of 0.82 (95% CI 0.87-0.93), in favor of D-containing regimens. If only studies (2 trials, 588 pts) are considered, in which D is added to a platinum/5-FU doublet, the HR is 0.79 (95% CI 0.64-0.98) in favor of the D-containing regimen. Comparison 3) 2 trials, 401 pts, with a HR of 0.85 (95% CI 0.68-1.06) in favor of the C-containing-regimen. Comparison 4) 2 trials, 1497 pts, with a HR of 0.89 (95% CI 0.80-1.0) in favor of the S-1-containing regimen. Comparison 5) 1 trial, 220 pts, with a HR of 0.82 (0.47-1.45) in favor of the O-containing regimen. Conclusions: All different chemotherapy combinations including I, D, O or oral 5-FU prodrugs are valid treatment options for mAGC. Among the comparisons analyzed above, only D-containing combinations, in which D was added to a single-agent or two-drug (platinum/5-FU) combination show a significant advantage in overall survival as compared to regimens without D.
Quality breast screening begins with quality technologists: Exploring workplace satisfaction among mammographic technologists.
Authors: Katie Marsh, Thad Benefield, Danielle Durham, J. Michael Bowling, Louise Henderson
Journal: Journal of Clinical Oncology (2014)

53 Background: To provide a quality patient experience, radiologists depend on the technologists’ skillset and interactions with patients, both of which may be impacted by satisfaction in the workplace. We identified factors related to the technologists’ job satisfaction, separately for lead and non-lead technologists. Methods: We sent a 50-item survey to 912 mammographic technologists (238 lead and 674 non-lead) throughout North Carolina. Survey items included questions on education and training, work experience, interaction with radiologists and other technologists, and job satisfaction. Job satisfaction was based on a 5-point scale ranging from 1 (strongly agree) to 5 (strongly disagree) for questions on workplace decision making and control, supervisor support, and performance feedback. Using a regression tree analysis, we identified factors related to technologist job satisfaction. All variables significant in the regression tree analysis (p-value&lt;0.05) were included in a linear regression model. Results: A total of 433 mammographic technologists responded to the survey (response rate 47.5%; 95% CI 44.2-50.7). Of these, 128 were lead (response rate 53.8%; 95% CI 47.4-60.1) and 305 were non-lead (response rate 45.3%; 95% CI 41.5-49.0). The mean job satisfaction among lead and non-lead technologists was 1.96 (SD 0.72; range 1 to 4.25). Linear regression analyses revealed that for lead and non-lead technologists, hours of administrative work (p&lt;0.0001), having frequent communication with radiologists (p=0.01), and having a mentor in the workplace (p=0.002) were related to increased job satisfaction. Being a lead technologist was associated with higher job satisfaction (p=0.0004). The number of diagnostic mammograms performed per week was inversely related to job satisfaction for lead technologists (p=0.002). Conclusions: There were little differences in factors that influence mammographic technologists’ job satisfaction for lead versus non-lead technologists. Future studies should explore if technologists’ job satisfaction affects recall rates and patient perceptions of quality care.
The Molecular and Cellular Processes of Tumor Cell-Mediated Tumor Angiogenesis and Vasculogenesis,
Authors: Quansheng Zhou, Zhifei Cao, Meimei Bao, Graduate student, Bingxue Shang, Graduate student, Gaochuan Zhang, Yanyan Pan, Jian Tu, Graduate student, Ruifang Liu, Graduate student, Di Yu, Graduate student, Pengda Guo, Graduate student, Ping Yang
Journal: Blood (2011)
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): The efficacy and its correlation with circulating endothelial cells.
Authors: T. Ueno, N. Masuda, S. Kamigaki, T. Morimoto, S. Nakamura, K. Kuroi, H. Iwata, S. Ohno, S. Tanaka, M. Toi
Journal: Journal of Clinical Oncology (2011)

618 Background: Neoadjuvant endocrine therapy has been increasingly employed in clinical practice to improve surgical outcomes in postmenopausal women with ER-positive breast cancer. Addition of metronomic cyclophosphamide (CPA) to letrozole (LET) has been suggested to be more active than LET alone in elderly pts. We conducted a phase II study to assess the efficacy and safety of the combination of LET and metronomic CPA and to examine the association between its efficacy and changes in circulating endothelial cell (CEC) and its progenitor cell (CEP) counts. Methods: Postmenopausal pts aged ≥60 yrs with ER-positive (≥10%) breast cancer (T2-4N0-1M0) were eligible. Pts received LET (2.5mg daily) and CPA (50mg p.o. daily) for 24 wks before surgery. Treatment responses were assessed every 8 wks by palpation and ultrasound. The primary endpoint was objective response rate (ORR). Secondary endpoints included breast conserving rate (BCR), safety, disease free survival and overall survival. CECs and CEPs were measured in 37 pts by flow cytometry and CellSearch system (Veridex LLC, NJ) before and 8 and 24 wks after the initiation of the treatment. Results: Forty-one pts (median age 70 yrs) were enrolled between Feb 2008 and Sep 2009. Five pts had HER2-positive (IHC3+ or FISH+) cancers. Three pts discontinued the treatment due to disease progression, comorbidity and voluntary discontinuation. The median exposure time was 5.6 months. ORR was 65.9% (27/41) both by ultrasound and by palpation. BCR was 75.6% (31/41). Major adverse events included Gr 3 leukocytopenia (1 pt), Gr 2 joint pain (2), Gr 2 osteoporosis (1) and Gr 2 allergic reaction (1). CEC counts by CellSearch system increased during the treatment in non-responders (p=0.043) but not in responders. CEP (CD31+CD34+CD133+CD45dim) counts became higher during the treatment in responders than in non-responders (p= 0.041). Conclusions: The combination of LET and CPA can be a promising treatment option for postmenopausal pts with ER-positive breast cancer. Measuring CECs and CEPs during treatment would be useful for treatment monitoring.
Development of a genetically modifiable epithelial in-vitro culture system from human embryonic lung epithelial stem cells: towards human lung regeneration in end-stage respiratory failure
Authors: Marko Z Nikolić, Jo-Anne Johnson, Dawei Sun, Oriol Caritg, Usua Laresgoiti, Jane Brady, George Allen, Adam Giangreco, Emma L Rawlins
Journal: The Lancet (2017)
Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).
Authors: Timothy J. Hobday, Rui Qin, Malcolm J. Moore, Diane Lauren Reidy, Jonathan R. Strosberg, Hedy Lee Kindler, Manisha H. Shah, Heinz-Josef Lenz, Andreas Kaubisch, Helen X. Chen, Charles Erlichman
Journal: Journal of Clinical Oncology (2013)

4032 Background: PNET has long had few effective therapies other than chemotherapy. Placebo-controlled phase III trials of the mTOR inhibitor everolimus and the VEGF/PDGF receptor inhibitor sunitinib noted improved progression-free survival (PFS). However, objective response rates (RR) with these agents are still &lt;10%. Preclinical studies suggest enhanced anti-tumor effects with combined mTOR and VEGF targeted therapy. Methods: We conducted a phase II trial of the mTOR inhibitor TEM (25 mg IV q week) and the VEGF-A monoclonal antibody BEV (10 mg/kg IV q 2 weeks) in patients (pts) with well or moderately differentiated PNET and progressive disease by RECIST within 7 months of study entry. Co primary endpoints were RR and 6-month PFS. Planned enrollment was 50 patients, with interim analysis for futility after the first 25 evaluable pts. Pts had no prior mTOR or VEGF targeted agents, ECOG PS 0-1, and adequate hematologic and organ function. Continued octreotide was allowed, but not required. Prior interferon, embolization, and ≤ 2 chemotherapy regimens were allowed. Results: 55 pts were eligible for response assessment. Confirmed PR was documented in 20 of 55 patients (37%). 44 of 55 (80%) patients were progression-free at 6 months. Of 49 pts evaluable for this endpoint, 12 month PFS is 49%. 15 patients remain on therapy. For evaluable patients, the most common grade 3-4 adverse events attributed to therapy were hypertension (18%), hyperglycemia (13%), fatigue (11%). leukopenia (9%), headache (9%), proteinuria (7%), and hypokalemia (7%). Conclusions: The combination of TEM/BEV has substantial activity in a multi-center phase II trial with RR of 37%, well in excess of single targeted agents in PNET. 6-month PFS was a notable 80% in a population of patients with RECIST criteria progression within 7 months of study entry. Phase III trials of combined VEGF/mTOR inhibition in PNET should be pursued. Clinical trial information: NCT01010126.
Case-control phase II clinical trial to assess safety and efficacy of the same antineoplastic treatment(s) in fit elderly compared with adult patients with cancer at different sites.
Authors: E. Massa, A. Dessi', M. Dessi', C. Madeddu, L. Orgiano, F. M. Tanca, G. Astara, G. Mantovani
Journal: Journal of Clinical Oncology (2011)

e19738 Background: We designed a case-control phase II open, prospective non-randomized trial in “fit” elderly (≥65 yo) cancer patients compared to well-matched adult (45-65 yo) cancer patients to assess whether the same standard antineoplastic treatment could achieve comparable results as for safety and efficacy. The planned sample size was 125 patients per arm. Endpoints were: safety, QoL, PFS, ORR, dose intensity. Methods: Only “fit” patients at MGA were included. Inclusion criteria for elderly: histological diagnosis of cancers with both advanced disease with measurable lesions or radically resected (adjuvant); life expectancy >3 mo.; adequate baseline functional parameters; written informed consent. Inclusion criteria for adults: the same as for elderly plus ECOG-PS 0-1. Results: At December 2010, 52 patients were enrolled, 26 elderly and 26 adults, all evaluable for toxicity. Elderly patients clinical characteristics: M/F ratio 13/13; mean age 70.5 ± 4.7 y. Adult patients: M/F ratio, 12/14; mean age 54 ± 6.1 y. Tumor sites were: colo-rectal, head and neck, NHL, gastric, uterus, breast, lung, prostate, colangiocarcinoma, pancreas, ovarian; 92.4% of patients were stage IV, 3.8% stage III and 3.8% stage II. In the elderly no grade 4 toxicity whilst nonhematological grade 3 toxicities were observed in 15.4% of patients. In the adults, grade 4 hematological and nonhematological toxicity were observed in 3.8% of patients, respectively; grade 3 hematological toxicity in 38.5% of patients and non hematological toxicities in 34.7% of patients. The difference was statistically significant (p=0.023) in favour of the elderly. At December 2010, 36 patients were assessable for response: the ORR was 55.6% for elderly and 38.9% for adults. No differences were observed as regards quality of life and dose intensity between the two groups. PFS was 10.1 mo. (3-12+ mo) for elderly and 8.57 mo. (3-12+) for adults. Conclusions: At this preliminarly planned interim-analysis, the results seem to suggest that elderly “fit” cancer patients can benefit from antineoplastic treatment both for safety and efficacy not differently from adults.
Impact of the New Anti-Myeloma Drugs on Outcome of Allogeneic Stem-Cell Transplantation with Reduced-Intensity Conditioning in Patients with High-Risk Multiple Myeloma
Authors: Jean El-Cheikh, Roberto Crocchiolo, Jean Marie Boher, Sabine Furst, Anne Marie Stoppa, Catherine Faucher, Luca Castagna, Angela Granata, Claire Oudin, jean Marc schiano De Colella, Diane Coso, Reda Bouabdallah, Didier Blaise
Journal: Blood (2011)
Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists’ (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC).
Authors: Charles J. Ryan, Mark R. Green, Susan L. Britton, Arden Buettner, Maria Lankford, Douglas Neely
Journal: Journal of Clinical Oncology (2014)

492 Background: During 2013 we assessed PPrefs for 2nd line therapy among 294 MOs based on age and outcome with 1st line TKI management for mccRCC using a validated, proprietary, live, case-based market research tool. A core case scenario with 3 1st line therapy outcomes - objective response; stable disease (SD); progressive disease (PD) -was constructed. Data were acquired using blinded audience response technology. Research support sources were double blinded. Methods: Core case–43 y.o.with recurrent disease in lung and bone 4 years after nephrectomy for ccRCC. PS 1. No brain mets. CrCl 79 ml/min. Scenarios tested (S1, S2, etc.): S1: 9 month objective PR with sunitinib/pazopanib 1st line. S2: 4 months stable disease with pazopanib 1st line. S3: Progression at 8 weeks with sunitinib 1st line. Results: Data from events 1 - 3 are shown in Table. Conclusions: Majority of 2nd line prescribing is mTOR-based with everolimus preferred over temsirolimus. Use of a TKI as 1st salvage after 1st line TKI is preferred by 38–51% of MOs when 1st line response is an extended objective PR. There is very limited preference for sequential TKIs when the best initial response is SD for &lt; 6 months or PD as best response. Current no specific TKI is the dominant PPrefs among MOs in this 1st salvage setting. [Table: see text]